Fundsmith LLP Sells 445,899 Shares of IDEXX Laboratories, Inc. $IDXX

Fundsmith LLP lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 30.4% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,019,887 shares of the company’s stock after selling 445,899 shares during the period. IDEXX Laboratories accounts for approximately 3.9% of Fundsmith LLP’s holdings, making the stock its 15th largest position. Fundsmith LLP’s holdings in IDEXX Laboratories were worth $536,909,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. SHP Wealth Management bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $26,000. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $26,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories in the second quarter valued at about $25,000. Elevation Wealth Partners LLC boosted its position in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after acquiring an additional 32 shares during the period. Finally, Wormser Freres Gestion grew its stake in shares of IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 47 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the subject of several analyst reports. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group raised their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Citigroup lifted their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Finally, Barclays cut their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Stock Performance

IDXX opened at $554.99 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98. The company has a 50-day simple moving average of $559.01 and a 200 day simple moving average of $573.33. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $43.72 billion, a price-to-earnings ratio of 39.03, a P/E/G ratio of 2.96 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.